News


09/08/14, Adempas Safety and Sustained Benefits of Adempas® From Bayer Confirmed by Results of Long-Term Studies Analysis of long-term extension studies CHEST-2 and PATENT-2 confirms long-term safety profile of riociguat over two years in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH) / Results demonstrate sustained improvements with riociguat in patients with CTEPH and PAH more

TB Alliance presents the results of the ReMoxTB study

Since 2008, Global Alliance for TB Drug Development – in short: TB Alliance – has been studying a new combination of active substances for the treatment of tuberculosis

more

EU verification logo for reputable online pharmacies

From July the European Commission is introducing a Europe-wide logo to help customers identify legitimate internet providers. more

"Young people want self-determination": Parliamentary Evening in Berlin

What do young people worldwide wish for the future?

more

Bayer Clinical Trials

Information about Bayer sponsored clinical studies is available at

Facebook

Facebook Banner

Follow us on Facebook

more

Links


http://www.bayerpharma.com/en/index.php?n=irp

Copyright © Bayer Pharma AG